News
GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...
British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...
In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.
UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation’s largest health insurer suspended its ...
With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...
1don MSN
UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...
Researchers found people given a shingles vaccine had a 23% lower risk of cardiovascular events, including stroke, heart ...
3h
Capital Market on MSNGSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/shareProfit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...
More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.
Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...
The head of UnitedHealth Group is stepping down, ending a rocky four years marked by rising medical costs, a major ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results